India Attracts MNC Drug Makers As Vaccine Market Growth Sector
This article was originally published in PharmAsia News
Executive Summary
India is fast becoming attractive to multinational pharmaceutical companies as a place to market vaccines, once relegated to the back burner as among the less-profitable of product lines. GlaxoSmithKline, Novartis and Pfizer are looking at the market potential in India as they see vaccines as one of the more profitable segments of their drug lines. Vaccine sales in India are projected to grow at an annual rate of at least 16 percent, soon becoming a $1 billion market. Three-fifths of the vaccine market in India is pediatric. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.